Navigation Links
Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference
Date:11/24/2009

FRANKLIN, Mass., Nov. 24 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the 13th Annual Biotech and Specialty Pharmaceuticals Conference, sponsored by the New York Society of Securities Analysts, at 2:05 on December 1, 2009. The conference is being held at the offices of the New York Society of Security Analysts, 1177 Avenue of the Americas, New York, NY.

For further information about this conference, please contact Derly Vargas at 646-871-3405 or dvargas@nyssa.org.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.


10 Forge Parkway
Franklin, MA 02038, USA
Tel: 1+ 877-476-6878
Fax: 1+ 508-553-8760
www.echotx.com

© 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide.


For More Information:
Patrick T. Mooney, M.D.
Chairman and Chief Executive Officer
(508)-530-0329

SOURCE Echo Therapeutics, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
3. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
4. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
5. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
6. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
7. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
8. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
9. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
10. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
11. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a Makro ... list for its expertise in eClinical Solutions. DDi has built its solution competency ... needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory and ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):